MSN: UC, UC Health launching clinical trial to study effectiveness of COVID-19 vaccine

Vaccine uses a genetic code to produce proteins that may generate protective antibodies

UC and UC Health are hosting a Phase 3 clinical trial to evaluate the effectiveness of a vaccine for COVID-19. UC is one of 90 sites across the United States selected for the study, which will administer the vaccine to volunteer participants and monitor its efficacy in eliciting an immune response that provides protection from COVID-19. The study is led by Carl Fichtenbaum, MD, and Maggie Powers-Fletcher, PhD, both of the UC College of Medicine Division of Infectious Diseases. 

Read the MSN report.

Other coverage:

Impact Lives Here

The University of Cincinnati is leading public urban universities into a new era of innovation and impact. Our faculty, staff and students are saving lives, changing outcomes and bending the future in our city's direction. Next Lives Here.

Stay up on all UC's COVID-19 stories, read more #UCtheGood content, or take a UC virtual visit and begin picturing yourself at an institution that inspires incredible stories.

Related Stories

3

WVXU: Find your CPAP annoying? UC researchers are working on a...

April 22, 2024

Dr. Liran Oren is leading a research team at the University of Cincinnati developing a VortexPAP machine that takes advantage of vortex airflow technology. A preliminary clinical study with current CPAP users demonstrated that the VortexPAP can deliver the pressure levels that are used in the subjects’ CPAP therapy, but the mask is more comfortable to wear. It has a minimalistic design that is less intrusive and barely touches the patient’s face.

Debug Query for this